PT  - JOURNAL ARTICLE
AU  - Hajjar, Ihab
AU  - Liu, Chang
AU  - Jones, Dean P.
AU  - Uppal, Karan
TI  - Untargeted metabolomics reveals sugar and homocysteine dysregulations in prodromal AD
AID  - 10.1101/2020.02.23.20025064
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.23.20025064
4099  - http://medrxiv.org/content/early/2020/02/26/2020.02.23.20025064.short
4100  - http://medrxiv.org/content/early/2020/02/26/2020.02.23.20025064.full
AB  - Introduction Altered metabolism may occur early in Alzheimer’s disease (AD). We used untargeted high-resolution metabolomics in the cerebrospinal fluid (CSF) in mild cognitive impairment (MCI) to identify these alterations.Methods CSF from 92 normal controls and 93 MCI underwent untargeted metabolomics using high-resolution mass spectrometry with liquid chromatography. Partial least squares discriminant analysis was used followed by metabolite annotation and pathway enrichment analysis (PES). Significant features were correlated with disease phenotypes using spearman correlation.Results We identified 294 features differentially expressed between the 2 groups and 94 were annotated. PES showed that pathways related to sugar regulation (N-Glycan, p=0.0007; sialic acid, p=0.0014; Aminosugars, p=0.0042; galactose, p=0.0054) homocysteine regulation (p=0.0081) were differentially activated and significant features within these pathways correlated with disease phenotypes.Conclusion We identified a metabolic signature characterized by impairments in sugar and homocysteine regulation in prodromal AD. Targeting these changes may offer new therapeutic approaches to ADResearch in ContextSystematic review: The authors searched PUBMED and Google Scholar for previous reports of metabolomics and Alzheimer’s disease. Search Terms included: mild cognitive impairment, Alzheimer’s disease “AND” metabolism, metabolomics. This search identified multiple small studies that have conducted untargeted metabolomics in AD. This search resulted in the following findings: Prior studies have either included small samples, used targeted approaches, or focused on plasma profiling. In this study, we conducted a case-control untargeted high resolution metabolomic study on the CSF of a larger sample of normal cognition and mild cognitive impairment.Interpretation: We discovered that pathways in sugar metabolism, homocysteine and tyrosine were dysregulated in AD. Further, features that were significantly different between MCI and normal cognition had different patterns of association with cognitive, neuroimaging and Amyloid and tau biomarkers.Future direction: These pathways offer new potential targets for ADHighlightsMetabolic signature is detectable in prodromal ADMultiple sugar metabolism pathways are dysregulated in prodromal AD.S-adenosylmethionine is under- and S-adenosylhomocysteine is overexpressed in ADCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health [Grants number RF1AG051633, RF1AG057470, R01AG049752, R01AG042127Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesALl data will be made available at SYNAPSE in 2020. https://www.synapse.org/